We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+14.45%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$3.02B
AUM Growth
-$134M
(-4.3%)
Cap. Flow
-$450M
Cap. Flow
% of AUM
-14.91%
Top 10 Holdings %
Top 10 Hldgs %
49.86%
Holding
60
New
11
Increased
11
Reduced
17
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stryker
SYK
|
+$131M |
| 2 |
Cigna
CI
|
+$111M |
| 3 |
AGN
Allergan plc
AGN
|
+$101M |
| 4 |
CVS Health
CVS
|
+$91.5M |
| 5 |
Medtronic
MDT
|
+$87.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$133M |
| 2 |
Merck
MRK
|
+$119M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$114M |
| 4 |
Elevance Health
ELV
|
+$96.2M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$85.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Zimmer Biomet
ZBH
$18.4B
| $279M | 9.27% |
2,188,750
+206,000
| +10% | +$24.5M |
|
|
2
Merck
MRK
$321B
| $171M | 5.67% |
2,524,506
-1,860,494
| -42% | -$119M |
|
|
3
Medtronic
MDT
$110B
| $166M | 5.51% |
1,689,850
+942,580
| +126% | +$87.1M |
|
|
4
Regeneron Pharmaceuticals
REGN
$76B
| $162M | 5.36% |
400,000
-225,000
| -36% | -$85.6M |
|
|
5
Stryker
SYK
$133B
| $155M | 5.16% |
875,000
+768,710
| +723% | +$131M |
|
|
6
Cigna
CI
$76.1B
| $125M | 4.14% |
+600,000
| New | +$111M |
|
7
HCA Healthcare
HCA
$85.7B
| $118M | 3.92% |
850,000
-350,000
| -29% | -$43.6M |
|
|
AGN
8
DELISTED
Allergan plc
AGN
| $117M | 3.9% |
616,660
+550,450
| +831% | +$101M |
|
9
Labcorp
LH
$25.9B
| $106M | 3.5% |
708,011
-339,589
| -32% | -$51.7M |
|
10
Intuitive Surgical
ISRG
$126B
| $104M | 3.44% |
541,380
+13,350
| +3% | +$2.37M |
|
|
11
CVS Health
CVS
$134B
| $101M | 3.34% |
+1,279,760
| New | +$91.5M |
|
12
Pacira BioSciences
PCRX
$1.06B
| $95.6M | 3.17% |
1,945,540
-909,673
| -32% | -$39.3M |
|
13
UnitedHealth
UNH
$383B
| $92.7M | 3.08% |
348,520
-58,380
| -14% | -$15.2M |
|
14
LivaNova
LIVN
$4.45B
| $86.2M | 2.86% |
695,110
-104,890
| -13% | -$12.4M |
|
|
CELG
15
DELISTED
Celgene Corp
CELG
| $83.8M | 2.78% |
936,168
-16,502
| -2% | -$1.46M |
|
|
16
Elevance Health
ELV
$81.6B
| $83.4M | 2.77% |
304,270
-370,730
| -55% | -$96.2M |
|
17
Quest Diagnostics
DGX
$25.9B
| $79.4M | 2.63% |
735,930
-261,650
| -26% | -$28.7M |
|
18
Edwards Lifesciences
EW
$50B
| $79M | 2.62% |
+1,361,145
| New | +$66.6M |
|
|
HRC
19
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $76.3M | 2.53% |
+807,760
| New | +$75.8M |
|
20
DexCom
DXCM
$28.8B
| $67.9M | 2.25% |
1,898,720
-559,800
| -23% | -$17.4M |
|
|
RDUS
21
DELISTED
Radius Health, Inc.
RDUS
| $63.8M | 2.12% |
3,584,580
+1,559,580
| +77% | +$35.3M |
|
|
AERI
22
DELISTED
Aerie Pharmaceuticals
AERI
| $63.5M | 2.11% |
1,032,127
-282,163
| -21% | -$18.1M |
|
23
Madrigal Pharmaceuticals
MDGL
$11.4B
| $56.3M | 1.87% |
262,860
+65,579
| +33% | +$16.5M |
|
|
XENT
24
DELISTED
Intersect ENT, Inc
XENT
| $56.1M | 1.86% |
1,950,000
+681,150
| +54% | +$20.5M |
|
25
Boston Scientific
BSX
$68.4B
| $54M | 1.79% |
1,402,950
+695,090
| +98% | +$24.3M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q3 2018 Portfolio in Review
As of Q3 2018, HealthCor Management held 60 positions worth $3.02B, down 4.3% from $3.15B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
HealthCor Management withdrew a net $450M in Q3 2018, closing 19 positions and reducing 17 holdings. Its most notable exit was Baxter International, an estimated $133M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 88% a quarter earlier.
Against the trend, HealthCor Management opened a new position in Cigna worth $125M.
- HealthCor Management's largest Q3 2018 buy was Cigna: 600,000 shares worth $125M.
- HealthCor Management added most to Stryker in Q3 2018, an estimated $131M increase.
- HealthCor Management's biggest Q3 2018 reduction was Merck, cutting an estimated $119M.
- HealthCor Management fully exited Baxter International in Q3 2018, selling an estimated $133M.
- HealthCor Management's ten largest holdings make up 50% of its $3.02B portfolio in Q3 2018.
- HealthCor Management opened 11 new positions and closed 19 in Q3 2018.
- HealthCor Management's portfolio value fell 4.3% quarter-over-quarter to $3.02B.
Based on HealthCor Management's 13F filing for Q3 2018, filed 15 Nov 2018.